Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.56 USD
Change Today -0.14 / -5.19%
Volume 232.3K
CRIS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

curis inc (CRIS) Key Developments

Curis, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Year 2015

Curis, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $2,082,504 compared to $4,801,285 a year ago. Net loss from operations was $7,369,416 compared to $1,544,787 a year ago. Net loss was $8,128,693 or $0.06 per basic and diluted share compared to $1,895,785 or $0.02 per basic and diluted share a year ago. The decrease in Revenue was primarily due to a decrease in license fee revenues due to a $3 million milestone payment that Curis earned from Genentech/Roche upon achievement by Genentech/Roche of certain development objectives during the second quarter of 2014. Offsetting these decreases, royalty revenues recorded on Genentech/Roche's net sales of Erivedge increased to $2.0 million in the second quarter of 2015 as compared to $1.8 million during the same period in 2014. For the six months, the company reported total revenues of $3,740,836 compared to $6,085,918 a year ago. Net loss from operations was $38,390,965 compared to $6,298,130 a year ago. Net loss was $39,976,916 or $0.34 per basic and diluted share compared to $7,459,721 or $0.09 per basic and diluted share a year ago. The company has revised its 2015 financial guidance for research and development expenses for 2015. The company currently expects that these expenses will be in the range of $30 to $35 million for 2015. The company had previously estimated that these expenses would range from $37 to $42 million. As a result, the company currently expects to end 2015 with cash, cash equivalents and investments of $72 to $77 million versus its previous estimate of $65 to $70 million.

Curis, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Curis, Inc. announced that they will report Q2, 2015 results at 9:00 AM, Eastern Standard Time on Aug 06, 2015

Curis, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Curis, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Curis Seeks Acquisition

Curis, Inc. (NasdaqGM:CRIS) has filed a Follow-on Equity Offering in the amount of $30.00 million. Its intend to use the net proceeds from the sale of any securities offered under this prospectus for general corporate purposes unless otherwise indicated in the applicable prospectus supplement. General corporate purposes may include to conduct further preclinical testing and clinical studies of our product candidates, to fund other research and development expenses, the in-licensing of individual drug candidates or drug programs, the acquisition of companies or businesses that complement our business, repayment and refinancing of debt, working capital and capital expenditures has filed a Follow-on Equity Offering in the amount of $30.00 million. Its intend to use the net proceeds from the sale of any securities offered under this prospectus for general corporate purposes unless otherwise indicated in the applicable prospectus supplement. General corporate purposes may include to conduct further preclinical testing and clinical studies of our product candidates, to fund other research and development expenses, the in-licensing of individual drug candidates or drug programs, the acquisition of companies or businesses that complement our business, repayment and refinancing of debt, working capital and capital expenditures

Curis, Inc.(NasdaqGM:CRIS) added to Russell 2000 Index

Curis, Inc. will be added to Russell 2000 Index

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRIS:US $2.56 USD -0.14

CRIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.65 USD -0.03
CTI BioPharma Corp $1.55 USD -0.03
Cytokinetics Inc $7.04 USD -0.16
MELA Sciences Inc $1.19 USD 0.00
Navidea Biopharmaceuticals Inc $2.00 USD +0.03
View Industry Companies
 

Industry Analysis

CRIS

Industry Average

Valuation CRIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 43.0x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CURIS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.